IceCure Medical (NASDAQ:ICCM - Get Free Report) is expected to be posting its Q4 2024 quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect IceCure Medical to post earnings of ($0.07) per share and revenue of $1.07 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.
IceCure Medical (NASDAQ:ICCM - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. On average, analysts expect IceCure Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
IceCure Medical Trading Up 0.5 %
ICCM stock traded up $0.01 during midday trading on Friday, hitting $1.11. The stock had a trading volume of 221,593 shares, compared to its average volume of 520,089. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The business has a fifty day moving average price of $1.32 and a two-hundred day moving average price of $0.98. IceCure Medical has a 1-year low of $0.48 and a 1-year high of $1.66. The firm has a market cap of $61.61 million, a P/E ratio of -3.83 and a beta of 0.37.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $2.50 target price on shares of IceCure Medical in a research report on Friday.
Read Our Latest Stock Analysis on ICCM
About IceCure Medical
(
Get Free Report)
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Read More
Before you consider IceCure Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IceCure Medical wasn't on the list.
While IceCure Medical currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
